What do systematic reviews say?

Intravenous vs oral cyclophosphamide

Intravenous showed no clear difference in adverse events: hair loss compared with oral cyclophosphamide (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.19 [0.04, 1.03]
  2 studies · 83 participants
  Low